Corbus制药控股 CRBP 深 沪
等待开盘 02-07 09:30:00 美东时间
7.50
+0.110
+1.49%
华盛通- 最 高9.57
- 今 开7.53
- 成交量 5.39万股
- 最 低 7.33
- 昨 收 7.39
- 总市值 93.75万
- 52周最高 20.56
- 市盈率 静 --
- 换手率 43.13%
- 52周最低 4.64
- 委 比 80.38%
- 总股本 0.00亿
- 历史最高 61.90
- 量 比 1.73
- 振 幅 30.31%
- 历史最低 0.05
- 每 手 1
- 风险率 2.81%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Corbus Pharmaceuticals Holdings shares are trading lower after the company announced a proposed public offering.
Corbus Pharmaceuticals Holdings shares are trading lower after the company anno...
2025-10-31 04:49
Corbus Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
Corbus Pharmaceuticals CEO Yuval Cohen will present a corporate update at the Jefferies Global Healthcare Conference on June 4, 2025, and participate in investor meetings. The company focuses on oncology and obesity with a pipeline including CRB-701, CRB-601, and CRB-913.
2025-05-22 12:00
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Tenon Medical (NASDAQ:TNON) shares increased by 28.2% to $5.16 during ...
2024-09-25 22:42
Novo Nordisk's Monlunabant Data Drags Stocks Of Smaller Players
Novo Nordisk announced positive Phase 2a trial results for monlunabant, showing significant weight loss with a 10 mg dose. However, investors reacted to limited gains at higher doses. Corbus Pharmaceuticals and Skye Bioscience stocks dropped as all three companies explore CB1 inhibition in obesity treatment.
2024-09-21 03:18
Crude Oil Moves Higher; Sable Offshore Shares Slide
U.S. stocks traded mostly lower toward the end of trading, with the Nasdaq Comp...
2024-09-21 02:16
Gold Gains Over 1%; Battalion Oil Shares Spike Higher
U.S. stocks traded mixed midway through trading, with the Nasdaq Composite fall...
2024-09-21 00:39
Corbus Pharma (CRBP) Stock Drops 60% After Novo Nordisk's Cannabinoid-Based Weight Loss Drug Trial Disappoints
Corbus Pharmaceuticals and Novo Nordisk stocks plunge following cannabinoid receptor drug trials, raising concerns over weight loss results.
2024-09-21 00:37
RBC Capital Reiterates Outperform on Corbus Pharmaceuticals, Maintains $82 Price Target
RBC Capital analyst Brian Abrahams reiterates Corbus Pharmaceuticals (NASDAQ:CRBP) with a Outperform and maintains $82 price target.
2024-09-20 22:50
US Stocks Edge Lower; FedEx Earnings Miss Views
U.S. stocks traded slightly lower this morning, with the Dow Jones falling arou...
2024-09-20 21:46
